Home

Letters, Testimony & Comments

The 10th Anniversary of the Sarbanes-Oxley Act, Jeffrey S. Hatfield, President and Chief Executive Officer, Vitae Pharmaceuticals
Jeffrey S. Hatfield, President and Chief Executive Officer, Vitae Pharmaceuticals On behalf of the Biotechnology Industry...
July 26 2012
NASDAQ Delisting Standards: SEC requests comments on NASDAQ’s proposal to temporarily suspend delisting standards
September 29, 2009
RE: SEC Release No. 34-60611 Dear Deputy Secretary Harmon: On behalf of its members, the Biotechnology Industry Organization (“...
September 29 2009
BIO Comment Letter to SEC Regarding IFRS Roadmap
April 20, 2009
Re: Release No. 33-8982; File No. S7-27-08; Roadmap for the Potential Use of Financial Statements Prepared in Accordance with...
April 20 2009
BIO comments on the proposed rulemaking, SEC Release No. 34-58572, by the Securities and Exchange Commission
October 27, 2008
Re: SEC Release No. 34-58572 Dear Chairman Cox: On behalf of its members, the Biotechnology Industry Organization (“BIO...
October 27 2008
Abusive Naked Short Selling: SEC responds to excessive market fluctuations during the financial crisis
October 27, 2008
Dear Chairman Cox: On behalf of its members, the Biotechnology Industry Organization (“BIO”) is pleased to provide comments...
October 26 2008
BIO applaudes the SEC’s recent rulemaking regarding investor protections against abusive "naked" short selling for all public companies.
September 22, 2008
Dear Chairman Cox and Director Thomsen: On behalf of its members, the Biotechnology Industry Organization (“BIO”) would...
September 22 2008
Pilot Circuit Breaker Proposal: SEC issues proposal on pilot circuit breaker program to combat abusive short selling
Dear Chairman Schapiro: The Biotechnology Industry Organization (BIO) thanks the Securities and Exchange Commission (SEC or Commission)...
IFRS Roadmap: SEC requests comments on U.S. conversion to a set of global accounting standards
Re: Release No. 33-8982; File No. S7-27-08; Roadmap for the Potential Use of Financial Statements Prepared in Accordance with...

Letters, Testimony & Comments

The 10th Anniversary of the Sarbanes-Oxley Act, Jeffrey S. Hatfield, President and Chief Executive Officer, Vitae Pharmaceuticals
July 26 2012
Jeffrey S. Hatfield, President and Chief Executive Officer, Vitae Pharmaceuticals On behalf of the Biotechnology Industry...
NASDAQ Delisting Standards: SEC requests comments on NASDAQ’s proposal to temporarily suspend delisting standards
September 29 2009
RE: SEC Release No. 34-60611 Dear Deputy Secretary Harmon: On behalf of its members, the Biotechnology Industry Organization (“...
BIO Comment Letter to SEC Regarding IFRS Roadmap
April 20 2009
Re: Release No. 33-8982; File No. S7-27-08; Roadmap for the Potential Use of Financial Statements Prepared in Accordance with...
BIO comments on the proposed rulemaking, SEC Release No. 34-58572, by the Securities and Exchange Commission
October 27 2008
Re: SEC Release No. 34-58572 Dear Chairman Cox: On behalf of its members, the Biotechnology Industry Organization (“BIO...
Abusive Naked Short Selling: SEC responds to excessive market fluctuations during the financial crisis
October 26 2008
Dear Chairman Cox: On behalf of its members, the Biotechnology Industry Organization (“BIO”) is pleased to provide comments...
More Letters, Testimony & Comments →

Press Releases

BIO Praises Rep. Michael Fitzpatrick on Introduction of Fostering Innovation Act
July 20 2012
Washington, D.C. (July 20, 2012) – Today, Representative Michael Fitzpatrick (R-PA) introduced H.R. 6161, the...
BIO Unveils Strategic Initiative to Speed Scientific Breakthroughs, Develop Cures and Grow the Bio-Economy
June 29 2011
WASHINGTON, D.C. (Wednesday, June 29, 2011) - The Biotechnology Industry Organization (BIO) released today a summary...
BIO to Ring NASDAQ Closing Bell on February 15
February 11 2011
WASHINGTON, D.C. (Friday, February 11, 2011) - The Biotechnology Industry Organization (BIO) today announced that...
BIO Commends SEC Efforts to Combat Illegal “Naked” Short Selling
September 30 2008
WASHINGTON, D.C. (Tuesday, September 30, 2008) - The Biotechnology Industry Organization (BIO) today released...
BIO Lauds Provisions to Give Small Companies SARBOX Relief and R&D Tax Credit Provisions
February 28 2008
Home Owndership, Manufacturing and Economic Growth (HOME) Act Mends Problems for Biotech WASHINGTON, D.C. (...
More Press Releases →